homepage-top-section

The CAN-COVID study will assess the efficacy of using canakinumab for the treatment of a type of severe immune overreaction known as cytokine release syndrome (CRS) in people

The breakthrough therapy status will allow using of mobocertinib by patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has advanced on or after

The regulator has approved Sanofi’s biologics licence application (BLA) for MenQuadfi meningococcal (Groups A, C, Y, W) conjugate vaccine to prevent invasive meningococcal disease in persons aged two

Sponsored by Novartis, the trial will recruit around 440 patients to assess the efficacy of malaria drug to treat hospitalised patients with COVID-19 disease. Novartis’ generics and biosimilars

The regulator has approved Tukysa in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who

The companies have signed a letter of intent to enter into collaboration for the development of a novel coronavirus vaccine by using their technologies. GSK CEO Emma Walmsley

As part of the deal, Alnylam will secure up to $2bn from Blackstone for the advancement of its RNAi medicines, which are believed to have the potential to

The clinical study, dubbed COLCORONA, will assess whether colchicine will serve as an effective treatment to prevent the phenomenon of major inflammatory storm present in adults suffering from

Under the binding agreement, the companies will work together to provide solutions for coronaviruses, including SARS-CoV-2, the novel coronavirus responsible for COVID-19. GSK will make an equity investment